Obesity Surgery

, Volume 29, Issue 1, pp 353–355 | Cite as

Comorbidity Remission Following Intragastric Dual Balloon Placement

  • Luis Garcia
  • Sean Vajanaphanich
  • John M. MortonEmail author
Brief Communication


The intragastric dual balloon was FDA approved in 2015 for the treatment of obesity. The objective of this study was to report the weight loss, comorbidity remission, and biochemical improvements experienced by 28 patients following intragastric dual balloon placement at a single institution between September 2015 and June 2017. Demographic data were collected preoperatively. Anthropometric, clinical, and biochemical data were collected preoperatively and 3 and 6 months postoperatively. Two patients were lost to data follow-up. Participants experienced significant improvements in blood pressure and lipid profiles, in addition to substantial weight loss 6 months after balloon insertion. The results of this study underscore the promise of the intragastric dual balloon as an efficacious intervention for weight loss and comorbidity remission in patients with early-stage obesity.


Intragastric balloons ReShape Bariatric surgery Weight loss Obesity 


Compliance with Ethical Standards

This study was approved by the appropriate university institutional review board, and participants completed written, informed consent.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–9. Scholar
  2. 2.
    ASGE Bariatric Endoscopy Task Force, ASGE Technology Committee, Abu Dayyeh BK, et al. Endoscopic bariatric therapies. Gastrointest Endosc. 2015;81(5):1073–86. Scholar
  3. 3.
    Palmisano S, Silvestri M, Melchioretto B, et al. Intragastric balloon device: weight loss and satisfaction degree. Obes Surg. 2016;26(9):2131–7. Scholar
  4. 4.
    Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;288:1–8.Google Scholar
  5. 5.
    Ponce J, Nguyen NT, Hutter M, et al. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-2014. Surg Obes Relat Dis. 2015;11(6):1199–200. Scholar
  6. 6.
    Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961. Scholar
  7. 7.
    Genco A, López-Nava G, Wahlen C, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg. 2013;23(4):515–21. Scholar
  8. 8.
    Martins Fernandes FA, Carvalho GL, Lima DL, et al. Intragastric balloon for overweight patients. JSLS. 2016;20(1):e2015.00107. Scholar
  9. 9.
    Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):377–88. Scholar
  10. 10.
    Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA. 2002;288(22):2793–6. ReviewCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Stanford University School of MedicineStanfordUSA

Personalised recommendations